Century Therapeutics, Inc. (IPSC): Price and Financial Metrics

Century Therapeutics, Inc. (IPSC): $8.85

0.46 (+5.48%)

POWR Rating

Component Grades













Add IPSC to Watchlist
Sign Up

Industry: Biotech



in industry

IPSC Stock Price Chart Interactive Chart >

Price chart for IPSC

IPSC Price/Volume Stats

Current price $8.85 52-week high $32.90
Prev. close $8.39 52-week low $7.32
Day low $8.08 Volume 46,700
Day high $8.89 Avg. volume 106,797
50-day MA $10.91 Dividend yield N/A
200-day MA $16.59 Market Cap 520.82M

Century Therapeutics, Inc. (IPSC) Company Bio

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Latest News Stream

Event/Time News Detail
Loading, please wait...

IPSC Latest Social Stream

Loading social stream, please wait...

View Full IPSC Social Stream

Latest IPSC News From Around the Web

Below are the latest news stories about Century Therapeutics Inc that investors may wish to consider to help them evaluate IPSC as an investment opportunity.

Century Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be available on the Events & Presentations page of Century’s we

Yahoo | February 9, 2022

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE ) and Century Therapeutics Inc (NASDAQ: IPSC ), an analyst at BofA Securities said in a note on Tuesday. The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares. The analyst rates Century a Buy with a $34 price target. The Biopharma Thesis: Fate''s To-Date Progress Is Encouraging: Fate''s pipeline of NK assets are currently in the clinic for liquid tumors, Ahmad said in a note. These assets have shown robust response rates and a manageable safety profile, he added. A recent clinical update from the 2021 ASH conference vouches for the redosing potential of NK cells, the ana...

Benzinga | February 8, 2022

What''s Behind Bristol Myers Squibb''s Latest Partnership?

The big drugmaker is gaining access to Century Therapeutics'' off-the-shelf CAR-T programs.

The Motley Fool | January 22, 2022

What's Behind Bristol Myers Squibb's Latest Partnership?

Bristol Myers Squibb (NYSE: BMY) has made some big acquisitions in the past, and it's now hinting that more deals could be on the way. The pharmaceutical giant recently announced a smaller licensing agreement with Century Therapeutics (NASDAQ: IPSC) instead of a big acquisition. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss what's behind Bristol Myers Squibb's latest partnership.

Yahoo | January 22, 2022

Inside the deal: Why Century Therapeutics picked Bristol Myers Squibb for its first Big Pharma mega-deal

The partnership could result in a multibillion-dollar payday for the Philadelphia cell therapy company.

Yahoo | January 14, 2022

Read More 'IPSC' Stories Here

IPSC Price Returns

1-mo -26.43%
3-mo -33.01%
6-mo -48.06%
1-year N/A
3-year N/A
5-year N/A
YTD -44.20%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5747 seconds.